OncoSec Medical Inc (ONCSQ)

[guti]

yes, if that's what needs to be done. However, the Patent that Oncosec owns wont change and that is what makes up the ImmunoPulse platform. They will license that platform to anyone that wants to use it in combination with their drug, as will be the case with Merck and Keytruda. I imagine that is the main reason why Merck decided not to take part in the P2b trial. Oncosec will not be selling a drug or an Interleukin since they actually have a license from the company that produces it. Therefore, the money will come from the device itself and its use through a license agreement.